YS-49

YS-49 is a PI3K/Akt (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells. YS-49 inhibits angiotensin II (Ang II) -stimulated proliferation of VSMCs via induction of heme oxygenase (HO) -1. YS-49 is also an isoquinoline compound alkaloid, has a strong positive inotropic action through activation of cardiac β-adrenoceptors[1][2][3].

Product Specifications

CAS Number

[132836-42-1]

UNSPSC

12352005

Hazard Statement

H302

Target

Adrenergic Receptor; Akt; Angiotensin Receptor; PI3K

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling; PI3K/Akt/mTOR

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Endocrinology

Assay Protocol

https://www.medchemexpress.com/ys-49.html

Purity

99.98

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 10 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

OC1=CC2=C(C(CC3=C4C=CC=CC4=CC=C3)NCC2)C=C1O.[H]Br

Molecular Formula

C20H20BrNO2

Molecular Weight

386.28

Precautions

H302

References & Citations

[1]Sun JJ, Kim HJ, Seo HG, et al. YS49,1- (alpha-naphtylmethyl) -6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, regulates angiotensin II-stimulated ROS production, JNK phosphorylation and vascular smooth muscle cell proliferation via the induction of heme oxygenase-1. Life Sci. 2008;82 (11-12) :600-7.|[2]Kang YJ, et al. Prevention of the expression of inducible nitric oxide synthase by a novel positive inotropic agent, YS 49, in rat vascular smooth muscle and RAW 264.7 macrophages. Br J Pharmacol. 1999 Sep;128 (2) :357-64.|[3]Hsu YH, et al. RhoA-mediated inhibition of vascular endothelial cell mobility: positive feedback through reduced cytosolic p21 and p27. J Cell Physiol. 2014 Oct;229 (10) :1455-65.